Accueil/Actions/LLY

LLY

USD

Eli Lilly and Company Common Stock

$899.665+8.255 (0.926%)

Prix en Temps Réel

Healthcare

Drug Manufacturers - General

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$891.410

Haut

$915.220

Bas

$883.640

Volume

6.58M

Fondamentaux de l'Entreprise

Capitalisation Boursière

806.5B

Industrie

Drug Manufacturers - General

Pays

United States

Statistiques de Trading

Volume Moyen

4.52M

Bourse

NYQ

Devise

USD

Intervalle sur 52 Semaines

Bas $623.78Actuel $899.665Haut $935.63

Rapport d'Analyse IA

Dernière mise à jour: 3 nov. 2025

Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

Eli Lilly (LLY): Navigating Growth Amid Competitive Obesity Drug Landscape

Market Snapshot

Current Price: $896.53 (as of 2025-11-03) 52-Week Range: $623.78 - $935.63 Volume Surge: 5.4M shares traded today vs. average of 4.5M

Key Trends Driving Recent Performance

Obesity Drug Dominance:

LLY announced a €2.6B Dutch plant to boost production of its weight-loss pill orfaglipron, signaling aggressive scaling.
Partnerships like the Walmart Zepbound retail rollout (mid-Nov 2025) expand market access.

Analyst Optimism:

27 analysts maintain "Buy" ratings; average price target of $919.

Actualités Connexes

5 nov. 2025 · 06:37

Reuters

Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter

Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker's new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.

Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter

4 nov. 2025 · 20:20

Reuters

Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports

Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss drugs at $149 per month, in exchange for Medicare coverage, Endpoints News reported on Tuesday, citing sources familiar with the matter.

Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports

4 nov. 2025 · 14:35

CNBC

Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer

The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.

Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer

4 nov. 2025 · 06:04

Reuters

Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer.

Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight

3 nov. 2025 · 17:07

Reuters

Novo Nordisk says Metsera bid won't raise antitrust issues

Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.

Novo Nordisk says Metsera bid won't raise antitrust issues

CNBC

3 nov. 2025 · 16:39

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.

Reuters

3 nov. 2025 · 13:35

Lilly to build $3 billion Dutch plant to boost weight-loss pill production

Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other oral medicines.